Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated
mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated …

The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single
agent activity in heavily pretreated relapsed and refractory multiple myeloma (MM). However, …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Purpose: Novel therapeutic agents have significantly improved the survival of patients with
multiple myeloma. Nonetheless, the prognosis of patients with multiple myeloma who …

Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on
multiple myeloma cells. The aim of this study was to investigate the clinical implications and the …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. …

Although survival of multiple myeloma patients has at least doubled during recent years, most
patients eventually relapse, and treatment at this stage may be particularly complex. At the …

Vaccination guidelines for patients treated for hematological diseases are typically conservative.
Given their high risk for severe COVID-19, it is important to identify those patients that …

Despite recent treatment improvements, multiple myeloma remains an incurable disease.
Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of …

The CD38-targeting antibody daratumumab has strong activity against multiple myeloma (MM),
but is associated with a modest increase in infectious complications. 1, 2 Normal plasma …